Eisai and Biogen are now working on the next steps after the TGA confirmed its non-approval of lecanemab for the treatment of mild cognitive impairment due to Alzheimer’s disease and early Alzheimer’s disease. …
Eisai and Biogen working on next steps after TGA confirms non-approval of Alzheimer’s therapy
March 4, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
This exchange on the HTA Review was about as underwhelming as it sounds
October 9, 2025 - - Latest News -
AusBiotech unveils international conference program for Australia’s biggest week in biotech
October 9, 2025 - - Australian Biotech -
Life sciences industry calls for stronger national strategy to support trials and innovation
October 9, 2025 - - Latest News -
Officials outline ongoing measures to address ADHD medicine shortages
October 9, 2025 - - Latest News -
Pharmaceutical spending to rise by around $10 billion, but still lose ground to other programs
October 9, 2025 - - Latest News -
Australian company reports positive outcome from collaboration
October 8, 2025 - - Australian Biotech -
CUREator opens $33 million funding round with CSL and AbbVie partnership
October 8, 2025 - - Latest News